Acting for VC investor into BioTech venture, Inoviv
We acted for a new seed-stage UK VC fund on its investment into Inoviv, a BioTech company developing bespoke biomarker tests to identify patients and demonstrate treatment efficacy for novel therapies.
Inoviv claims its tests: “support pharmaceutical companies in running successful clinical trials and in maximising access to marketed therapies”.
Deal/project: Seed investment
Other lawyers and advisors: Cooley acted for the company